| Title: |
Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis |
| Authors: |
Terrier, Benjamin; Pugnet, Grégory; de Moreuil, Claire; Bonnotte, Bernard; Benhamou, Ygal; Chauveau, Dominique; Besse, Marie-Charlotte; Duffau, Pierre; Limal, Nicolas; Néel, Antoine; Urbanski, Geoffrey; Jourde-Chiche, Noémie; Martin-Silva, Nicolas; Campagne, Julien; Mekinian, Arsène; Schleinitz, Nicolas; Ackermann, Felix; Fauchais, Anne-Laure; Froissart, Antoine; Le Gallou, Thomas; Uzunhan, Yurdagul; Viallard, Jean-François; Bérezné, Alice; Chiche, Laurent; Taillé, Camille; Direz, Guillaume; Durel, Cécile-Audrey; Godmer, Pascal; Trad, Salim; Lambert, Marc; de Menthon, Mathilde; Quéméneur, Thomas; Cadranel, Jacques; Charles, Pierre; Dossier, Antoine; Jilet, Léa; Guillevin, Loïc; Abdoul, Hendy; Puéchal, Xavier; French Vasculitis Study Group |
| Source: |
ISSN: 0003-4819 ; Annals of internal medicine, (2025. |
| Publication Year: |
2025 |
| Collection: |
Université de Genève: Archive ouverte UNIGE |
| Description: |
Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Rituximab has emerged as the standard of care in other types of ANCA-associated vasculitis, but controlled studies on its use in EGPA are yet lacking. Objective: To compare rituximab with conventional strategy for the induction of remission in patients with EGPA. Design: Phase 3, multicenter, randomized, controlled, double-blind, superiority trial. (ClinicalTrials.gov: NCT02807103). Setting: France. Participants: Patients with a diagnosis of EGPA, newly diagnosed or relapsing disease at the time of screening, with active disease defined as a Birmingham Vasculitis Activity Score (BVAS) of 3 or greater. Intervention: Glucocorticoids plus rituximab (1 g 2 weeks apart) compared with the conventional strategy (glucocorticoids alone or in combination with cyclophosphamide in severe forms) for induction of remission. Measurements: The primary end point was remission defined as a BVAS, version 3, of 0 and a prednisone dose of 7.5 mg/d or less at day 180. Secondary end points included duration of remission during the study, average daily glucocorticoid dose, and safety. Results: A total of 105 participants were randomly assigned. Thirty-three (63.5%) patients in the rituximab group achieved the primary end point compared with 32 (60.4%) in the control group (relative risk, 1.05 [95% CI, 0.78 to 1.42]; P = 0.75). Results were similar at day 360. The mean duration of remission was 48.5 ± 6.51 weeks in the rituximab group and 49.1 ± 7.42 weeks in the conventional strategy group ( P = 0.41). All relapse and major relapse rates were similar between the 2 groups. There was no statistically significant difference in the average daily glucocorticoid dose and no statistically significant differences in the rates of adverse events between the treatment groups. Limitation: Design not appropriate to answer the question of equivalence between rituximab and cyclophosphamide in patients ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/40720835; unige:187245 |
| Availability: |
https://archive-ouverte.unige.ch/unige:187245 |
| Rights: |
info:eu-repo/semantics/restrictedAccess |
| Accession Number: |
edsbas.7005B304 |
| Database: |
BASE |